Author Affiliations: Institute of Vascular Medicine, Li Ka Shing Institute of Health Sciences, S. H. Ho Cardiovascular Disease and Stroke Centre, Heart Education And Research Training (HEART) Centre and Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region (SAR).
We read with interest the meta-analysis by Komócsi et al, which reported that the use of factor Xa and direct thrombin inhibitors in patients receiving antiplatelet therapy after an acute coronary syndrome (ACS) was associated with a substantial increase in major bleeding and moderate reduction in ischemic events.1 However, there are a few issues we would like to highlight.
Kwong JSW, Yu C. New Oral Anticoagulants in Acute Coronary Syndromes: What Does a Meta-analysis Tell Us?. JAMA Intern Med. 2013;173(9):835-836. doi:10.1001/jamainternmed.2013.78